Publication: The heterogeneous landscape of ALK negative ALCL
Open/View Files
Date
2017
Published Version
Journal Title
Journal ISSN
Volume Title
Publisher
Impact Journals LLC
The Harvard community has made this article openly available. Please share how this access benefits you.
Citation
Mereu, Elisabetta, Elisa Pellegrino, Irene Scarfò, Giorgio Inghirami, and Roberto Piva. 2017. “The heterogeneous landscape of ALK negative ALCL.” Oncotarget 8 (11): 18525-18536. doi:10.18632/oncotarget.14503. http://dx.doi.org/10.18632/oncotarget.14503.
Research Data
Abstract
Anaplastic Large Cell Lymphoma (ALCL) is a clinical and biological heterogeneous disease including systemic ALK positive and ALK negative entities. Whereas ALK positive ALCLs are molecularly characterized and readily diagnosed, specific immunophenotypic or genetic features to define ALK negative ALCL are missing, and their distinction from other T-cell non-Hodgkin lymphomas (T-NHLs) can be controversial. In recent years, great advances have been made in dissecting the heterogeneity of ALK negative ALCLs and in providing new diagnostic and treatment options for these patients. A new revision of the World Health Organization (WHO) classification promoted ALK negative ALCL to a definite entity that includes cytogenetic subsets with prognostic implications. However, a further understanding of the genetic landscape of ALK negative ALCL is required to dictate more effective therapeutic strategies specifically tailored for each subgroup of patients.
Description
Other Available Sources
Keywords
anaplasticl large cell lymphoma, molecular classification, therapy, ALK negative
Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material (LAA), as set forth at Terms of Service